WITHUS PHARMACEUTICAL Co.,LTD. (KOSDAQ:330350)
South Korea · Delayed Price · Currency is KRW 7,250.00
-10.00 (-0.14%)
At close: Oct 2, 2026
KOSDAQ:330350 Ratios and Metrics
Market cap in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 1, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 95,698 | 113,802 | 92,943 | 128,366 | 123,616 | 138,481 | |
Market Cap Growth | 3.70% | 22.44% | -27.59% | 3.84% | -10.73% | -26.91% |
Enterprise Value | 93,386 | 114,670 | 101,308 | 130,632 | 113,324 | 119,353 |
Last Close Price | 7250.00 | 8620.00 | 7040.00 | 9730.00 | 9270.64 | 10388.65 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 1, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 12.02 | 22.91 | 19.43 | 16.13 | 49.86 | 32.48 |
PS Ratio | 0.86 | 1.07 | 0.91 | 1.60 | 1.91 | 2.41 |
PB Ratio | 0.92 | 1.16 | 1.00 | 1.42 | 1.49 | 1.71 |
P/TBV Ratio | 0.96 | 1.22 | 1.05 | 1.46 | 1.54 | 1.75 |
P/FCF Ratio | 25.26 | 20.76 | 12.79 | - | - | 102.25 |
P/OCF Ratio | 10.87 | 16.78 | 9.65 | - | 22.98 | 17.27 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 1, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 0.84 | 1.08 | 0.99 | 1.63 | 1.75 | 2.08 |
EV/EBITDA Ratio | 11.22 | 11.77 | 10.73 | 12.15 | 16.60 | 18.69 |
EV/EBIT Ratio | 22.92 | 20.25 | 17.90 | 16.52 | 23.23 | 24.43 |
EV/FCF Ratio | 24.65 | 20.91 | 13.94 | - | - | 88.13 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 1, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.18 | 0.19 | 0.26 | 0.22 | 0.26 | 0.29 |
Debt / EBITDA Ratio | 2.23 | 1.92 | 2.55 | 1.86 | 3.14 | 3.62 |
Debt / FCF Ratio | 4.90 | 3.42 | 3.31 | - | - | 17.06 |
Net Debt / Equity Ratio | -0.02 | -0.01 | 0.06 | 0.10 | -0.06 | -0.24 |
Net Debt / EBITDA Ratio | -0.28 | -0.07 | 0.55 | 0.82 | -0.75 | -3.03 |
Net Debt / FCF Ratio | -0.61 | -0.13 | 0.71 | -0.73 | 0.51 | -14.30 |
Asset Turnover | 0.79 | 0.79 | 0.77 | 0.64 | 0.54 | 0.51 |
Inventory Turnover | 2.22 | 2.14 | 2.31 | 2.52 | 3.07 | 2.98 |
Quick Ratio | 1.38 | 1.37 | 1.21 | 1.20 | 1.74 | 2.55 |
Current Ratio | 2.05 | 2.06 | 1.80 | 1.88 | 2.33 | 3.19 |
Return on Equity (ROE) | 7.96% | 5.20% | 5.22% | 9.19% | 3.02% | 5.41% |
Return on Assets (ROA) | 1.80% | 2.61% | 2.67% | 3.95% | 2.56% | 2.71% |
Return on Invested Capital (ROIC) | 4.00% | 5.79% | 5.34% | 7.78% | 4.17% | 6.84% |
Return on Capital Employed (ROCE) | 3.70% | 5.50% | 5.60% | 7.90% | 5.20% | 5.10% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 1, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 8.32% | 4.37% | 5.15% | 6.20% | 2.01% | 3.08% |
FCF Yield | 3.96% | 4.82% | 7.82% | -9.38% | -8.05% | 0.98% |
Payout Ratio | - | - | 27.57% | - | 25.53% | 9.90% |
Buyback Yield / Dilution | -0.04% | 0.14% | -0.14% | -0.09% | 0.10% | -59.55% |